Muy buen articulo!!! Los pacientes con Lupus tienen mas #ACV, los anticuerpos de #SAF por si solo son factores de riesgo. Acá les comparto una revisión de cochrane que resume la evidencia de Antiagregación vs Anticoagulación en #SAF y #ACV https://t.co/tOR
New from #CSO_Scotland https://t.co/b6oc2blU0s Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
"Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome." https://t.co/4LqKKbLnvS
RT @HHakeam: Cochrane review No role for DOACs in the prevention of stroke or thromboembolism in antiphospholipid syndrome https://t.co/E…
RT @HHakeam: Cochrane review No role for DOACs in the prevention of stroke or thromboembolism in antiphospholipid syndrome https://t.co/E…
RT @HHakeam: Cochrane review No role for DOACs in the prevention of stroke or thromboembolism in antiphospholipid syndrome https://t.co/E…
RT @HHakeam: Cochrane review No role for DOACs in the prevention of stroke or thromboembolism in antiphospholipid syndrome https://t.co/E…
RT @HHakeam: Cochrane review No role for DOACs in the prevention of stroke or thromboembolism in antiphospholipid syndrome https://t.co/E…
Anticoagulant drugs and/or antiplatelet drugs for reducing the risk of blood clots and… https://t.co/D0GDkePsXu
CochraneLibrary: Anticoagulant drugs and/or antiplatelet drugs for reducing the risk of blood clots and strokes in… https://t.co/Pfymn1Dwv7 https://t.co/My7CEMeyI1
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other… https://t.co/9yznS1vVqv